Perimenopause, Depression and TMS

Perimenopausal depression is a recognized clinical problem, and its front-line treatments are antidepressants and psychotherapy, with estrogen therapy showing antidepressant effects in perimenopausal women, particularly those with hot flashes. TMS fits later in that sequence. It is FDA-cleared for major depressive disorder in adults whose depression has not improved with antidepressant medication, and that indication applies regardless of menopausal stage.

What TMS does not have is perimenopause-specific evidence. A literature search for this review in October 2026 found no published sham-controlled trial of TMS designed for perimenopausal depression; a first pilot trial of theta-burst stimulation in the late menopause transition, aimed at mechanisms, cognition and mood, was registered in 2025. So TMS here rests on the general depression evidence, applied thoughtfully to a midlife woman's circumstances.

Why perimenopause is a window of risk

The perimenopause, which covers the early and late menopause transition and the early postmenopause, is now understood as a period of heightened vulnerability to depressive symptoms and major depressive episodes. In the Study of Women's Health Across the Nation (SWAN), women were two to four times more likely to have a major depressive episode when they were perimenopausal or early postmenopausal than when they were premenopausal, independent of prior depression, life stress and hormone levels.

History matters. A 2018 expert guideline on perimenopausal depression notes that most midlife women who have a major depressive episode during the perimenopause have had one before. A woman with recurrent depression entering her mid-forties is therefore someone to watch closely, and someone for whom prevention planning is worthwhile.

How it presents and how it is evaluated

Midlife depression usually looks like depression at any age, but it is often intertwined with menopausal symptoms such as hot flashes, night sweats and sleep disruption, along with the psychosocial pressures of midlife. Broken sleep alone can produce fatigue, irritability and poor concentration that mimic or worsen depression.

The 2018 guideline recommends identifying menopausal stage, assessing psychiatric and menopausal symptoms together, considering psychosocial factors and other diagnoses, and using validated screening instruments. In practice that means asking about cycle changes and vasomotor symptoms, screening for thyroid disease, anemia and other medical contributors, and reviewing alcohol use and sleep. The site's perimenopause psychiatry and menopause and mental health pages describe that evaluation; medical contributors to apparent treatment resistance are covered in ruling out medical causes before TMS.

Symptoms of the transition, or a depressive episode?

Not every low mood during perimenopause is major depression, and the distinction shapes treatment. Many women notice irritability, tearfulness or a shorter fuse that tracks with poor sleep and hot flashes and lifts when those improve. That pattern often responds to treating the menopausal symptoms and the sleep.

A major depressive episode is different in persistence and reach: most of the day, nearly every day, for weeks at a time, with loss of interest or pleasure and changes in sleep, appetite, energy, concentration, self-worth or thoughts of death. It affects work and relationships, and it does not resolve just because a few nights of sleep go better. When that picture is present, it deserves treatment as depression in its own right, whatever the hormonal context. TMS is relevant only to this second group, and only after standard treatment has fallen short.

Standard treatments, in order

Hormone decisions belong with a gynecologist or menopause specialist working alongside the psychiatrist, because they turn on vasomotor symptoms, bleeding patterns, and cardiovascular and breast cancer risk, not on mood alone. Sleep treatment deserves equal attention: CBT-I for menopausal insomnia explains why it comes first.

When TMS becomes a reasonable option

TMS enters the picture when major depression persists despite adequate treatment. Guidelines place it after first-line psychotherapy and medication have not worked: the 2023 Canadian (CANMAT) guideline rates rTMS a first-line option for treatment-resistant depression, and the American Psychiatric Association's 2010 guideline lists it among options to consider after medication non-response. CANMAT also allows TMS to be chosen earlier when medication tolerability is a concern or when it helped in a previous episode.

That tolerability point is relevant at midlife. Some women stop antidepressants because of weight change, sexual side effects or emotional blunting, at a stage of life when those effects can feel especially costly. For them, TMS can be a way forward that does not add another systemic medication. The trade-offs are compared in every treatment-resistant depression option compared, and the patient-facing view is in stopping antidepressants because of side effects.

TMS is also not a substitute for addressing hot flashes or insomnia. If night sweats are fragmenting sleep every night, treating them may do more for mood than any brain stimulation.

What the evidence in women does and does not show

There are a few relevant signals, none of them specific to perimenopause.

• In a large open-label NeuroStar registry, women did better than men, though the registry was not sham-controlled.
• In a 2019 meta-analysis of how long TMS benefit lasts, a higher proportion of women in a study predicted higher sustained response rates.
• For later life, a 2025 meta-analysis of 10 randomized trials in late-life depression generally found benefit over control on depression scores, response and remission.

None of these isolate the perimenopause. Whether response differs during the transition has not been tested in a dedicated trial. An Australian pilot trial (MenoStim) has been registered to study theta-burst stimulation in 72 women in the late menopause transition, with cognition and mood among its outcomes. Until such trials report, honest counseling says the evidence for TMS in depression includes women generally, and that its performance in perimenopause specifically is unmeasured.

Practical points for a midlife TMS course

• Time. A standard course is five sessions a week for six weeks plus a three-week taper, 36 sessions in total. Newer protocols can be shorter; see accelerated TMS.
• Sleep. Sleep deprivation is among the factors that lower the seizure threshold, so severe perimenopausal insomnia is worth addressing before and during a course.
• Medications. TMS is often given alongside antidepressants, and hormone therapy decisions can proceed in parallel; the evidence on combining treatments is in combining TMS with medication.
• After the course. Benefit fades for some people over months, so a relapse-prevention plan should be in place from the start. Durability data are in how long TMS results last.

If you are thinking about suicide or are in crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or go to the nearest emergency room.

Questions to raise with your psychiatrist

1. Is this a major depressive episode, or symptoms driven mainly by sleep loss and hot flashes?
2. Have my medication trials been adequate in dose and duration, and were side effects the reason any were stopped?
3. Should a menopause specialist weigh in on hormone therapy before or alongside the next step?
4. If TMS is proposed, what outcome will we track, and how will we judge whether it worked?
5. What is the plan for staying well afterward, given my history of previous episodes?

The longevity connection

The perimenopause is a turning point for long-term health, not only for mood. Sleep, metabolic health and cardiovascular risk all shift during these years, and untreated depression interacts with each of them. Treating a depressive episode fully, rather than settling for partial improvement, is part of protecting the decades ahead. The site's longevity psychiatry and perimenopause and metabolic health pages expand on that view, and TMS in an integrative practice shows how neuromodulation fits within a whole-person plan.

For the basics of how TMS works and who it is cleared for, see the TMS guide and the TMS overview.

Frequently asked questions

Is perimenopausal depression a real diagnosis?

Yes. Research such as the SWAN study shows women are more likely to have a major depressive episode during the menopause transition and early postmenopause than before it, and expert guidelines now address its evaluation and treatment.

Can TMS be used for depression during perimenopause?

Yes, under the standard indication for adults with major depression that has not improved with antidepressants. There is no separate perimenopause indication, and no dedicated trials in this group yet.

Should I try hormone therapy before TMS?

Estrogen therapy has evidence of antidepressant effects in perimenopausal women, especially with hot flashes, but it is not approved to treat depression. The decision depends on menopausal symptoms and medical risks and is best made with a menopause specialist and your psychiatrist together.

Can I take hormone therapy and have TMS at the same time?

Many patients continue their other treatments during TMS. Discuss every medication and supplement with the TMS team, which will review anything that affects seizure risk.

Does TMS work better in women?

In a large open-label registry, women did better than men, and a durability meta-analysis linked more women in a study to more sustained response. These findings are not specific to perimenopause.

Sources

1. FDA 510(k) K160703 and K161519. U.S. FDA, 2016. accessdata.fda.gov
2. K231926 510(k) Summary. U.S. FDA, 2024. accessdata.fda.gov
3. Clinical outcomes in a large registry of patients with major depressive disorder treated with Transcranial Magnetic Stimulation. J Affect Disord, 2020. pubmed.ncbi.nlm.nih.gov
4. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clinical Neurophysiology, 2021. europepmc.org
5. Repetitive transcranial magnetic stimulation for late-life depression: A systematic review and meta-analysis of randomized controlled trials. Journal of International Medical Research, 2025. europepmc.org
6. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition. American Psychiatric Association, 2010. psychiatryonline.org
7. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults. Canadian Journal of Psychiatry, 2024. pmc.ncbi.nlm.nih.gov
8. Durability of antidepressant response to repetitive transcranial magnetic stimulation: Systematic review and meta-analysis. Brain Stimulation, 2019. pubmed.ncbi.nlm.nih.gov
9. Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. Menopause, 2018. europepmc.org
10. Major depression during and after the menopausal transition: Study of Women's Health Across the Nation (SWAN). Psychological Medicine, 2011. europepmc.org
11. The MenoStim Trial: Study Protocol for a Randomised, Sham-Controlled, Double-Blinded, Pilot Clinical Trial Exploring the Neurophysiological, Cognitive, Mood and Biochemical Effects Associated with Non-Invasive Brain Stimulation During the Menopause Transition. BMJ Open, 2025. europepmc.org
12. Europe PMC search: (transcranial magnetic stimulation OR rTMS OR theta burst) AND (perimenopausal OR menopausal) AND depression, run 2026-10-07; no dedicated sham-controlled trial found. Europe PMC, 2026. europepmc.org

Educational information, not medical advice. Whether TMS or any treatment fits you is a decision to make with a psychiatrist who knows your history.